title: [Clinical investigation of famciclovir in chronic hepatitis B patients irresponsive to alpha interferon treatment].
abstract: OBJECTIVE
  To evaluate the efficacy and safety of famciclovir on the decreasing levels of serum HBV-DNA and ALT and HBeAg/antiHBe seroconversion in chronic hepatitis B patients irresponsive to 3 months treatment with alpha interferon.
  
  
  METHODS
  Two hundred and nineteen patients with chronic HBV infection, defined as positive HBsAg, HBeAg and HBV DNA, were enrolled and randomly half-and- half put into famciclovir and placebo groups. The two groups received either famciclovir 500 mg tid or a placebo treatment for 24 weeks, and then were followed-up for another 24 weeks with no treatment.
  
  
  RESULTS
  At the end of 24 weeks, the log value of HBV DNA dropped from 6.54+/-1.26 to 5.70+/-2.03 in the famciclovirt group and were elevated from 6.30+/-1.32 to 6.51+/-1.65 in the placebo group (P < 0.01). The rate of cases with persistence HBV DNA dropped 2 log of quantity in the famciclovir group and was 28.28% (28/99); it was 9.47% (9/95) in the placebo group (P < 0.01). Those with persistence negative HBV DNA was 28.28% (28/99) in the flamciclovir treated group and 14.74% (14/95) in the placebo group (P < 0.05). Those persistently being HBeAg negative were 7.69% (7/91) in the famciclovir treated group and 3.33% (3/90) in the placebo group (P > 0.05). The HBeAg/antiHBe seroconversion was 4.40% (4/91) in the famciclovir group and 2.22% (2/90) in the placebo group (P > 0.05). The percentage of cases with normal of ALT level was 15.15% in the famciclovir group and 6.35% in the placebo group (P < 0.05).
  
  
  CONCLUSIONS
  Famciclovir is effective in inhibiting HBV DNA replication and in decreasing serum ALT levels. The rate of HBeAg/antiHBe seroconversion in the famciclovir treated group was similar to that of the placebo group. Famciclovir was well tolerated without severe adverse effects during our treatment.
authors.affiliation: Department of Infectious Diseases, the Second Affiliated Hospital, Chongqing University of Medical Sciences, Chongqing 400010, China. wangzhiyi@vip.sina.com
authors.forename: Zhi-yi
authors.initials: ZY
authors.lastname: Wang
authors.forename: Shu-hua
authors.initials: SH
authors.lastname: Guo
authors.forename: Ding-feng
authors.initials: DF
authors.lastname: Zhang
authors.forename: You-rong
authors.initials: YR
authors.lastname: Zhao
authors.forename: Hong
authors.initials: H
authors.lastname: Ren
authors.forename: Xia-qiu
authors.initials: XQ
authors.lastname: Zhou
authors.forename: Dao-zhen
authors.initials: DZ
authors.lastname: Xu
authors.forename: Jing-yuan
authors.initials: JY
authors.lastname: Sun
authors.forename: Ji-lu
authors.initials: JL
authors.lastname: Yao
authors.forename: Wei-lun
authors.initials: WL
authors.lastname: Lu
mesh_terms: D015075:2-Aminopurine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D000077595:Famciclovir; D005260:Female; D005500:Follow-Up Studies; D006515:Hepatitis B virus / Q000502:physiology; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D014779:Virus Replication / Q000187:drug effects
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D015075:2-Aminopurine; D000077595:Famciclovir